National Institute For Clinical Excellence (NICE) has launched a special scheme which will help people suffering from macular degeneration to avail Novartis AG's, pricey eye drug Lucentis through cost effective scheme.
This move, follows a draft plan in which the National Health Service will pay for a maximum of 14 injections of Lucentis per eye, with Novartis agreeing to pay if any more are needed.
Although NICE estimates that 14 shots of Lucentis would be more than enough to improve the vision.
Lucentis is an expensive drug, which cost more than 10,000 pounds for each eye treated. It is the most effective drug which helps in the formation of new blood vessels in the macular degenerated patients.
Source: https://www.telegraph.co.uk/
Filed under Eye Treatment | Tags: eye, Lucentis, Macular Degeneration, NICE | Comment Below
Related?
Eye Drug Lucentis Recommended by UK's NICE to Treat Wet AMDJune 14th, 2007 Novartis AG's Lucentis drug against wet age-related macular degeneration (AMD) received a recommendation from the UK's National Institute for Health and Clinical Excellence (NICE) for use on the National Health Service. Lucentis should be used for about 20 pct of patients with AMD, a condition which causes sight loss and blindness, when both eyes are affected, NICE said in a statement last night.
Lucentis - Wet Macular Degeneration Drug is Highly Successful in Clinical TrialsJune 14th, 2006 Michels, a Palm Beach Gardens, Fla., ophthalmologist, has been treating some patients afflicted by the wet form of the disease with Lucentis, a Genentech Inc. drug that was placed on fast-track review by the Food and Drug Administration and could be approved this month.
Brand New Treatment For Macular DegenerationJuly 8th, 2006 It's the leading cause of blindness in people over the age of 50 and in our Healthy Living report a brand new treatment for Macular Degeneration that some are calling a miracle. Margie Puslipher suffers from Macular Degeneration and was on the verge of blindness.
Hope for Age Related Macular Degeneration with LucentisDecember 31st, 2005 Genentech Inc. has applied for U.S.
Macular Degeneration and its New Treatments October 11th, 2006 The results of two large, randomized clinical trials published October 5, 2006, in the New England Journal of Medicine demonstrate that the drug ranibizumab (Lucentis) is an effective treatment for neovascular macular degeneration, a complication of age-related macular degeneration that leads to the vast majority of legal blindness associated with the disorder. it is a disease of the retina that affects more than 9 million Americans and is a leading cause of blindness in people over 55.
Macular degeneration now restricted by lucentis treatmentJuly 6th, 2009 Caroline Tate of Charlotte can see her grandchildrens' faces, and enjoys the gift of vision that Lucentis has given her. In 2005 she was diagnosed to have macular degeneration.
Queensland Health Minister Backs Strategy for Rapid Cataract Surgery May 23rd, 2008 The Queensland health Minister Mr Stephen Robertson has supported the new strategy that is likely to be in favor of the patients of cataract surgery at the Herbey Bay Hospital. The strategy will be helpful for patients who have to wait for long hours for the surgery.
Eye care scheme for Boston University employeesApril 29th, 2009 Boston University's human resource office have set up an eye care benefit scheme for its employees through the New England Eye Institute(NEEI). The new eye care scheme will allow BU staffs to enjoy certain medical benefits.
